Progression-free survival end points in prostate cancer: are we truly making progress

被引：0
|
作者：
Madan, Ravi A. [1 ]
Posadas, Edwin M. [2 ]
Lee, Richard J. [3 ]
机构：
[1] NCI, Genitourinary Malignancies Branch, Bethesda, MD 20892 USA
[2] Samuel Oschin Comprehens Canc Inst, Cedars Sinai Med Ctr, Los Angeles, CA USA
[3] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Dept Med, Boston, MA USA
来源：
NATURE REVIEWS UROLOGY | 2024年
关键词：
PHASE-III; PREDNISONE; DOCETAXEL;
D O I：
10.1038/s41585-024-00902-x
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Recently, several therapeutic strategies in prostate cancer have been granted regulatory approval based on progression-free survival benefits alone, which is a relative change in the therapeutic development of prostate cancer treatments. Previously, overall survival was a requirement for approvals. Whether this approach is warranted or beneficial to patients remains unclear.
引用
收藏
页码：646 / 648
页数：3
相关论文
共 50 条
  • [1] Are We Making Progress in Lung Cancer Using Progression-Free Survival as a Surrogate End Point?
    Shyr, Yu
    Horn, Leora
    Berry, Lynne
    JAMA ONCOLOGY, 2015, 1 (02) : 202 - 203
  • [2] Prostate cancer: Validating radiographic progression-free survival
    Thoma C.
    Nature Reviews Urology, 2018, 15 (5) : 263 - 263
  • [3] MRI radiomics predicts progression-free survival in prostate cancer
    Jia, Yushan
    Quan, Shuai
    Ren, Jialiang
    Wu, Hui
    Liu, Aishi
    Gao, Yang
    Hao, Fene
    Yang, Zhenxing
    Zhang, Tong
    Hu, He
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [4] Rucaparib extends progression-free survival in metastatic prostate cancer
    Franke, Katharina
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2023, 148 (21) : 1341 - 1341
  • [5] Radiographic progression-free survival in the ACIS trial for prostate cancer
    Gilboa, Shai
    Bomze, David
    Markel, Gal
    Meirson, Tomer
    LANCET ONCOLOGY, 2022, 23 (01): : E3 - E3
  • [6] Before We Throw out Progression-Free Survival As a Valid End Point ...
    Stewart, David J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27) : 3426 - 3427
  • [7] Radiographic progression-free survival in the ACIS trial for prostate cancer reply
    Saad, Fred
    De Porre, Peter
    Brookman-May, Sabine
    Li, Jinhui
    McCarthy, Sharon A.
    Rathkopf, Dana E.
    LANCET ONCOLOGY, 2022, 23 (01): : E5 - E6
  • [8] Comment on "Rucaparib extends progression-free survival in metastatic prostate cancer"
    von Amsberg, Gunhild
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2023, 148 (21) : 1340 - 1341
  • [9] Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined
    Saad, E. D.
    Katz, A.
    ANNALS OF ONCOLOGY, 2009, 20 (03) : 460 - 464
  • [10] Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer
    Halabi, Susan
    Roy, Akash
    Rydzewska, Larysa
    Guo, Siyuan
    Godolphin, Peter
    Hussain, Maha
    Tangen, Catherine
    Thompson, Ian
    Xie, Wanling
    Carducci, Michael A.
    Smith, Matthew R.
    Morris, Michael J.
    Gravis, Gwenaelle
    Dearnaley, David P.
    Verhagen, Paul
    Goto, Takayuki
    James, Nick
    Buyse, Marc E.
    Tierney, Jayne F.
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (09)
12345